Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Major Shareholder Ra Capital Management, L.P. Acquires 824,600 Shares
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Major Shareholder Ra Capital Management, L.P. Acquires 824,600 Shares
Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Rating) major shareholder Ra Capital Management, L.P. purchased 824,600 shares of the company's stock in a transaction that occurred on Wednesday, December 14th. The stock was purchased at an average price of $5.46 per share, for a total transaction of $4,502,316.00. Following the purchase, the insider now owns 7,824,600 shares in the company, valued at $42,722,316. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
支点治疗公司(纳斯达克代码：FULC-GET Rating)的大股东Ra Capital Management，L.P.在12月14日星期三的一笔交易中购买了824,600股该公司股票。股票是以每股5.46美元的平均价格购买的，总交易额为4,502,316.00美元。收购完成后，这位内部人士现在拥有该公司7824,600股票，价值42,722,316美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在以下网址获得此超链接。持有公司10%以上股份的大股东必须披露他们在美国证券交易委员会上的销售和购买情况。
Ra Capital Management, L.P. also recently made the following trade(s):
Ra Capital Management，L.P.最近还进行了以下交易：
- On Friday, December 16th, Ra Capital Management, L.P. bought 1,341,420 shares of Fulcrum Therapeutics stock. The stock was purchased at an average cost of $5.42 per share, with a total value of $7,270,496.40.
- 12月16日，星期五，Ra Capital Management，L.P.购买了1,341,420股支点治疗公司的股票。这只股票的平均价格为每股5.42美元，总价值为7,270,496.40美元。
Fulcrum Therapeutics Price Performance
支点治疗药物性价比
Shares of FULC stock opened at $5.35 on Friday. Fulcrum Therapeutics, Inc. has a 1 year low of $3.21 and a 1 year high of $24.79. The firm has a fifty day moving average price of $6.37 and a 200-day moving average price of $6.69. The company has a market cap of $278.47 million, a price-to-earnings ratio of -2.09 and a beta of 1.96.
周五，FULC的股票开盘报5.35美元。支点治疗公司的一年低点为3.21美元，一年高位为24.79美元。该公司的50日移动均线价格为6.37美元，200日移动均线价格为6.69美元。该公司市值为2.7847亿美元，市盈率为-2.09倍，贝塔系数为1.96。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Institutional Trading of Fulcrum Therapeutics
Fulcrum治疗药物的机构交易
Several hedge funds have recently bought and sold shares of the stock. Sandia Investment Management LP purchased a new position in shares of Fulcrum Therapeutics during the 3rd quarter valued at about $40,000. Delphia USA Inc. purchased a new position in Fulcrum Therapeutics during the second quarter valued at approximately $58,000. SG Americas Securities LLC boosted its position in shares of Fulcrum Therapeutics by 207.1% in the second quarter. SG Americas Securities LLC now owns 13,173 shares of the company's stock worth $65,000 after purchasing an additional 8,884 shares during the period. AQR Capital Management LLC bought a new position in shares of Fulcrum Therapeutics in the second quarter worth approximately $68,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of Fulcrum Therapeutics in the third quarter worth $74,000. Institutional investors own 96.96% of the company's stock.
几家对冲基金最近买卖了该股的股票。桑迪亚投资管理公司在第三季度购买了支点治疗公司新的股票头寸，价值约40,000美元。德尔菲亚美国公司在第二季度购买了Fulcrum治疗公司的一个新头寸，价值约5.8万美元。SG America Securities LLC在第二季度将其在Fulcrum Treateutics的股票头寸增加了207.1%。在此期间，SG America Securities LLC额外购买了8,884股，目前拥有13,173股该公司股票，价值65,000美元。AQR资本管理有限责任公司在第二季度购买了价值约6.8万美元的支点治疗公司股票的新头寸。最后，AllSpring Global Investments Holdings LLC在第三季度购买了Fulcrum治疗公司价值7.4万美元的新股份。机构投资者持有该公司96.96%的股票。
About Fulcrum Therapeutics
关于支点治疗公司
(Get Rating)
(获取评级)
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
FULCRUM治疗公司是一家临床阶段的生物制药公司，专注于开发产品，以改善美国高度未得到满足的医疗需求领域的遗传性疾病患者的生活。它的候选产品是losmapimod，一种用于治疗面肩肩周肌营养不良的小分子；以及FTX-6058，一种研究中的口服胎儿血红蛋白诱导剂，用于治疗镰状细胞疾病和其他血红蛋白疾病，包括β-地中海贫血。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Fulcrum Therapeutics (FULC)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- 免费获取StockNews.com关于Fulcrum治疗(FULC)的研究报告
- MarketBeat：回顾一周12/12-12/16
- 哪两家蓝筹科技公司提高了他们的指引？
- 你应该担心埃隆·马斯克出售他持有的特斯拉股票吗？
- 拖拉机库存能否突破杯柄收购点？
- 现在不是购买Lennar的时候，但时机即将到来
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《支点治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Fulcrum治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。